Inflammation and degeneration in multiple sclerosis
- PMID: 14652785
- DOI: 10.1007/s10072-003-0170-7
Inflammation and degeneration in multiple sclerosis
Abstract
Multiple (MS) sclerosis is a chronic inflammatory demyelinating disease of the central nervous system with the pathological hallmarks of inflammation, demyelination, axon loss and gliosis. In the initial relapsing-remitting phase of the disease, the inflammatory-demyelinating component seems to predominate, whereas the progressive disease appears to be characterized by a neurodegenerative component leading to extensive neuroaxonal damage in the MS brain. Axon loss most likely determines the persistent neurological deficit in progressive MS. Recent studies pointed out that axon damage occurs early in the disease and during lesion development. Two different phases of axon degeneration were characterized, the first occurring during active myelin breakdown and the second in chronic demyelinated plaques in which the naked axon seems more susceptible to further damage. The exact mechanisms and effector molecules of axonal degeneration, however, are not yet defined, and an axon-protective therapy has not yet been established.
Similar articles
-
Protecting axons in multiple sclerosis.Mult Scler. 2008 Sep;14(8):1013-25. doi: 10.1177/1352458508091370. Epub 2008 Jul 16. Mult Scler. 2008. PMID: 18632772 Review.
-
From inflammation to degeneration: the lessons of clinical trials.Neurol Sci. 2003 Dec;24 Suppl 5:S295-7. doi: 10.1007/s10072-003-0178-z. Neurol Sci. 2003. PMID: 14652793 Review.
-
[Axonal damage and its significance for the concept of neurodegeneration in multiple sclerosis].Fortschr Neurol Psychiatr. 2011 Mar;79(3):161-70. doi: 10.1055/s-0029-1246014. Epub 2011 Mar 10. Fortschr Neurol Psychiatr. 2011. PMID: 21394707 Review. German.
-
Mitochondrial dysfunction plays a key role in progressive axonal loss in Multiple Sclerosis.Med Hypotheses. 2005;64(4):669-77. doi: 10.1016/j.mehy.2004.09.001. Med Hypotheses. 2005. PMID: 15694681
-
Axonal degeneration is an early pathological feature in autoimmune-mediated demyelination in mice.Microsc Res Tech. 2001 Mar 15;52(6):731-9. doi: 10.1002/jemt.1057. Microsc Res Tech. 2001. PMID: 11276125
Cited by
-
The complement and immunoglobulin levels in NMO patients.Neurol Sci. 2014 Feb;35(2):215-20. doi: 10.1007/s10072-013-1481-y. Epub 2013 Jul 24. Neurol Sci. 2014. PMID: 23881468
-
Therapeutic decisions in multiple sclerosis: moving beyond efficacy.JAMA Neurol. 2013 Oct;70(10):1315-24. doi: 10.1001/jamaneurol.2013.3510. JAMA Neurol. 2013. PMID: 23921521 Free PMC article. Review.
-
Visual Outcomes of Adding Erythropoietin to Methylprednisolone for Treatment of Retrobulbar Optic Neuritis.J Ophthalmic Vis Res. 2019 Jul 18;14(3):299-305. doi: 10.18502/jovr.v14i3.4786. eCollection 2019 Jul-Sep. J Ophthalmic Vis Res. 2019. PMID: 31660109 Free PMC article. Review.
-
Optic neuritis.Eye (Lond). 2011 Jul;25(7):833-42. doi: 10.1038/eye.2011.81. Epub 2011 Apr 29. Eye (Lond). 2011. PMID: 21527960 Free PMC article. Review.
-
Plasma levels of complement proteins from the alternative pathway in patients with age-related macular degeneration are independent of Complement Factor H Tyr⁴⁰²His polymorphism.Mol Vis. 2012;18:2288-99. Epub 2012 Aug 30. Mol Vis. 2012. PMID: 22969267 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical